Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07170787 | A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 104 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04632108 | A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 199 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY |
| 1 |
| Sep 11, 2025 |
| clinicaltrials |
| NCT06468358 | A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors(TRIGGERCD8) | recruiting | Phase 1 / Phase 2 | 194 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06187402 | A Study of LM-24C5 For Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 49 | LaNova Medicines LimitedINDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07158918 | ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 65 | ABL Bio, Inc.INDUSTRY | 3 | Sep 8, 2025 | clinicaltrials |
| NCT06209580 | AMT-253 in Patients With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 96 | Multitude Therapeutics Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07157956 | CVL006 Combination Therapy in Advanced Solid Tumors(CVL006-T1002) | not yet recruiting | Phase 1 / Phase 2 | 318 | Convalife (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07128576 | Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors | not yet recruiting | Phase 2 | 60 | Zhujiang HospitalOTHER | 0 | Sep 4, 2025 | clinicaltrials |
| NCT04685226 | A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 310 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 209 | Immuneering CorporationINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT07142837 | Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 153 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 27, 2025 | clinicaltrials |
| NCT06907043 | A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.(EIK1004-001) | recruiting | Phase 1 / Phase 2 | 130 | Eikon TherapeuticsINDUSTRY | 3 | Aug 19, 2025 | clinicaltrials |
| NCT05761223 | A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 | recruiting | Phase 1 / Phase 2 | 151 | 1ST Biotherapeutics, Inc.INDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07122063 | Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 266 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05888857 | MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.(TAYLOR) | not yet recruiting | Phase 2 | 102 | Institut BergoniéOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07070349 | A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 48 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT06480240 | A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 117 | OBI Pharma, IncINDUSTRY | 2 | Aug 8, 2025 | clinicaltrials |
| NCT07107633 | A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor. | recruiting | Phase 2 | 90 | Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.OTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT02304809 | Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations(AcSé) | active not recruiting | Phase 2 | 216 | UNICANCEROTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06105021 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 100 | Affini-T Therapeutics, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06543056 | A Study of ES014 in Subjects With Advanced Solid Tumors | recruiting | Phase 2 | 15 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05275777 | A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 66 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06208410 | A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 306 | Risen (Suzhou) Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05978102 | A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 183 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07077252 | Phase I/II Study of SCTB39G in Advanced Solid Tumours | not yet recruiting | Phase 1 / Phase 2 | 30 | Sinocelltech Ltd.INDUSTRY | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07061639 | A Study of QLS5133 Monotherapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 212 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 11, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06277219 | A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)(LIGHTSPEED-1) | recruiting | Phase 1 / Phase 2 | 150 | Latticon Antibody Therapeutics, IncINDUSTRY | 2 | Jul 8, 2025 | clinicaltrials |
| NCT07050641 | Phase I/II Study of SCTB39-1 in Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 110 | Sinocelltech Ltd.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT07049458 | Study of CHO-A04 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 62 | Cho Pharma Inc.INDUSTRY | 1 | Jul 3, 2025 | clinicaltrials |
| NCT06669117 | FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations | recruiting | Phase 1 / Phase 2 | 140 | Pierre Fabre MedicamentINDUSTRY | 9 | Jul 2, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT07030478 | A Study to Evaluate the Safety and Tolerability of EP0089 | not yet recruiting | Phase 1 / Phase 2 | 190 | Ellipses PharmaINDUSTRY | 0 | Jun 22, 2025 | clinicaltrials |
| NCT04946968 | Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers | active not recruiting | Phase 2 | 24 | National Cancer Centre, SingaporeOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT05888831 | A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Bristol-Myers SquibbINDUSTRY | 6 | Jun 11, 2025 | clinicaltrials |
| NCT07002502 | Immune Modulation With PRaG-1 Treatment | not yet recruiting | Phase 2 | 19 | Second Affiliated Hospital of Soochow UniversityOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT06987500 | A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment | recruiting | Phase 1 / Phase 2 | 132 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06653777 | Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells(AcSé PEMI) | recruiting | Phase 2 | 40 | UNICANCEROTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06603844 | First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | recruiting | Phase 1 / Phase 2 | 156 | Corbus Pharmaceuticals Inc.INDUSTRY | 2 | Jun 3, 2025 | clinicaltrials |
| NCT06943820 | AK129 Combination Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 230 | AkesoINDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT04706715 | LAG3 PET Imaging in Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 41 | University Medical Center GroningenOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06991478 | SK-NK Injection in Patients With Advanced Solid Tumors Accompanied by Malignant Ascites | not yet recruiting | Phase 1 / Phase 2 | 10 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 28, 2025 | clinicaltrials |
| NCT06992687 | A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors | enrolling by invitation | Phase 1 / Phase 2 | 30 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT05541822 | To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation | recruiting | Phase 2 | 178 | Abion IncINDUSTRY | 3 | May 22, 2025 | clinicaltrials |
| NCT05251714 | CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 44 | Treadwell Therapeutics, IncINDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT03673787 | A Trial of Ipatasertib in Combination With Atezolizumab(IceCAP) | active not recruiting | Phase 1 / Phase 2 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | May 14, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 12, 2025source: clinicaltrials